Quantitative connection between polyglutamine aggregation kinetics and neurodegenerative process in patients with Huntington’s disease

Table 1 Parameters and descriptive statistics derived from the regression analyses of Figures 4A and 6C

	%patients	intercept ±SE	slope ±SE	_add t ²	q	R ²	Ftest	P
SCA3	95.78	−7.3787 ± 0.424	0.0948 ± 0.00584	―	4.29	0.474	263.53	< 1.0 x 10^-41
HD	98.42	6.6856 ± 0.144	−0.0668 ± 0.00318	217	―	0.588	441.47	< 1.0 x 10^-60

SCA3: Ln[q –Ln(t_A)] = A^*x + Ln(μ_o) – A^*x_min + ϵ (Eq. 19).
HD: Ln(t_A² - _addt²)^1/2 = −bx + Ln(a^*) + bx_min⁺ + ϵ (Eq. 20).
% patients = percentage of all studied patients used to derive the model, SE = standard error, R² = coefficient of determination. Clinical data from patients with mutations in relevant genes, including 308 patients with SCA3 and 312 patients with HD, were derived from earlier reports [36–40].

ISSN: 1750-1326